Evolus (Evolus) GF Value Rank : 7 (As of May. 21, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Evolus GF Value Rank?

Evolus has the GF Value Rank of 7.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Evolus's GF Value Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolus's GF Value Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Evolus's GF Value Rank falls into.

Evolus GF Value Rank Related Terms

Thank you for viewing the detailed overview of Evolus's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus (Evolus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

EVL:Germany EVL:Germany

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.

Executives

David Moatazedi	director, officer: See Remarks	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Medytox Inc.	10 percent owner	78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Sandra Beaver	officer: Chief Financial Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar	officer: See Remarks	1618 STATION STREET, VANCOUVER A1 V6A 1B6
Vikram Malik	director	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Alphaeon 1 Llc	10 percent owner	4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman	director	8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank	director	C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail	officer: See Remarks	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Crystal Muilenburg	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart	director	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Michael M. Jafar	officer: Chief Marketing Officer	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614